Emergent BioSolutions Inc. EBS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 649.10M | 770.20M | 676.80M | 742.90M | 788.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 649.10M | 770.20M | 676.80M | 742.90M | 788.90M |
| Cost of Revenue | 367.10M | 381.50M | 355.20M | 375.40M | 404.40M |
| Gross Profit | 282.00M | 388.70M | 321.60M | 367.50M | 384.50M |
| SG&A Expenses | 193.20M | 191.70M | 190.80M | 196.60M | 205.70M |
| Depreciation & Amortization | 60.60M | 66.30M | 65.30M | 65.10M | 65.10M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 620.60M | 639.10M | 610.90M | 636.70M | 674.40M |
| Operating Income | 28.50M | 131.10M | 65.90M | 106.20M | 114.50M |
| Income Before Tax | -240.00M | -146.00M | 3.50M | 82.80M | 105.90M |
| Income Tax Expenses | 20.70M | 30.80M | 12.10M | 30.20M | 30.00M |
| Earnings from Continuing Operations | -260.70 | -176.80 | -8.60 | 52.60 | 75.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -260.70M | -176.80M | -8.60M | 52.60M | 75.90M |
| EBIT | 28.50M | 131.10M | 65.90M | 106.20M | 114.50M |
| EBITDA | 116.50M | 225.50M | 159.80M | 202.00M | 213.80M |
| EPS Basic | -5.04 | -3.44 | -0.17 | 0.95 | 1.41 |
| Normalized Basic EPS | 0.75 | 1.66 | 0.78 | 1.18 | 0.65 |
| EPS Diluted | -5.10 | -3.55 | -0.28 | 0.84 | 1.30 |
| Normalized Diluted EPS | 0.73 | 1.61 | 0.73 | 1.11 | 0.59 |
| Average Basic Shares Outstanding | 207.20M | 209.10M | 211.70M | 214.20M | 216.00M |
| Average Diluted Shares Outstanding | 211.80M | 217.00M | 219.60M | 220.40M | 222.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |